(S) -Cdc7-IN-18
(S) -Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S) -Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1) [1].
Product Specifications
CAS Number
2562329-13-7
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/s-cdc7-in-18.html
Solubility
10 mM in DMSO
Smiles
O=C1C2=C(NC([C@@]3([H])N4CCC(CC4)C3)=N1)C5=C(C6=CNN=C6CCC5)S2
Molecular Formula
C19H21N5OS
Molecular Weight
367.47
References & Citations
[1]Gang Li, et al. Tetracyclines as Cdc7 inhibitors. Patent WO2020239107A1.|[2]Li Gang, et al. Tetracyclic compounds as cdc7 inhibitors. WO2020239107A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDC
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942470-100 1x 100 µL
Perforin-1 (Pore Forming Protein) (Apoptosis Marker) (PRF1/2470), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400896-500 1x 500 µL
PDCD1 / PD1 / CD279 (Programmed Cell Death 1) (NAT105), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 